1. Market Research
  2. > Healthcare
  3. > Medical Device
  4. > Cardiovascular Devices Market Trends
  5. > MediPoint: Coronary Stents - EU Analysis and Market Forecasts

MediPoint: Coronary Stents - EU Analysis and Market Forecasts

Summary

The global coronary stents market is a dynamic, double-digit market that is saturated with numerous players developing innovative technologies. Rapid advances in the field of interventional cardiology along with the development of minimally invasive techniques have greatly expanded the potential of therapeutic applications. Coronary stents including bare metal, drug-eluting, covered and bioabsorbable stents can be used to treat coronary artery disease, and optimize outcomes.

The coronary stents market in the EU has an overall negative CAGR of 0.5% over the forecast period from 2011-2020. Similar to the US, the DES market in the EU has the largest share, where the DES market is four times that of the BMS market. Moving forward, GlobalData believes that the DES market will grow slowly due to the improved outcomes, the development of low-profile systems and the next generation of DES, and cost-savings due to the reduced need for repeat intervention.

In the EU, there is a strong dependency on reimbursement, which can vary between nations. German reimbursement has generally been strong for medical devices, and has been less of a problem. However, the other countries are keen to follow clinical outcomes carefully for adoption and product usage in order to obtain reimbursement.

Scope

- An overview of Coronary Stents, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized EU Coronary Stents market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020.
- Investigation of current and future market competition for Coronary Stents.
- Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
- Competitor assessment including device approval analysis and device sales forecasts.
- Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
- Analysis of unmet needs within the market and opportunities for future players.
- Technology trends evaluation to assess strength of pipeline.
- An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
- Company profiles including business description, financial overview and SWOT analysis.
- Coverage of key market players.
- Strategic assessment of the Coronary Stents sector through market impact analysis, future market scenario and company analysis.
- Direct quotes from Key Opinion Leaders (KOL) as well as doctors

Reasons to buy

- Understand the trends shaping and driving the EU Coronary Stents market.
- Realize device preferences of physicians who have performed the tests already.
- Access market sizing, forecasts and quantified growth opportunities in the US Coronary Stents market through 2018.
- Quantify candidate patient populations to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
- Perform benchmarking analysis of growth opportunities against currently marketed products.
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Take a comprehensive look at the market’s device pipeline and identify promising, paradigm-shifting products.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
- What’s the next big thing in the EU Coronary Stents market landscape? Identify, understand and capitalize.

Table Of Contents

MediPoint: Coronary Stents - EU Analysis and Market Forecasts
1 Table of Contents

2 Introduction 25
2.1 Catalyst 26
2.2 Related Reports 27
3 Industry Overview 28
3.1 Disease Overview 28
3.2 Clinical Outcomes 29
3.2.1 Treatment Guidelines 29
3.2.2 Treatment Modalities 30
3.3 Procedure Trends 44
3.3.1 European Union 45
3.4 Market Access 47
3.4.1 Regulatory Process 48
3.4.2 Physician Decision-Making Process 49
3.4.3 Role of Group Purchasing Organizations 53
3.4.4 Lack of Clinical Data 56
3.4.5 Regional-Level Control 58
3.4.6 Cost Considerations 58
3.4.7 Reimbursement Trends 59
3.5 Regulatory Issues/Recalls 64
3.5.1 Regulatory Issues 64
3.5.2 Product Recalls 65
3.6 Mergers and Acquisitions/ Key Partnerships 65
3.6.1 Medtronic and Covidien 65
3.6.2 Arterial Remodeling Technologies and Terumo Corporation 66
3.6.3 MicroPort Scientific Corporation and Cordis Corporation 66
3.6.4 Alvimedica and CID 67
3.6.5 ITGI Medical and Vascular Solutions 67
3.6.6 Terumo Corporation and Onset Medical Corporation 67
3.6.7 Atrium Medical and Getinge Group 68
3.6.8 C.R. Bard and ClearStream Technologies 68
3.6.9 Biosensors International and Devax, CardioMind, and JW Medical Systems 69
3.6.10 CeloNova Biosciences and Nexeon MedSystems 70
3.6.11 Medtronic and Invatec 70
3.6.12 Micell Technologies and Maxcor Lifescience 71
3.6.13 Boston Scientific Corporation and Guidant Corporation 71
3.6.14 Abbott Vascular and Guidant Corporation 71
3.6.15 Kaneka Corporation and Fujisawa Pharmaceuticals 72
3.7 Economic Impact of Coronary Artery Disease 72
3.7.1 European Union 73
3.8 Treatment Costs for Coronary Artery Disease 74
4 Unmet Needs 76
4.1 Need for Better Clinical Outcomes in Specific Lesions 76
4.1.1 Chronic Total Occlusions 76
4.1.2 Small-Vessel Coronary Lesions 77
4.1.3 Heavily-Calcified and Uncrossable/Undilatable Lesions 78
4.1.4 Bifurcation Lesions 78
4.1.5 Saphenous Vein Graft Intervention 79
4.2 Eliminating Mechanisms of Failure With Balloon Angioplasty 80
4.3 Late Myocardial Infarction After Stenting 80
4.4 Eliminating the Permanent Polymer 81
4.5 In-Stent Restenosis 82
4.6 Stent-In-Stent Procedures 84
4.7 Prolonged Dual Antiplatelet Therapy 85
4.8 Lack of Homogenous Drug Distribution 86
4.9 Delayed Stent Endothelialization 86
4.10 Negative Vessel Remodeling 87
4.11 Need for Effective Therapy for Specific Patient Populations 87
4.12 Addressing the Complications of Coronary Artery Bypass Grafting 88
5 Market Opportunity Analysis 89
5.1 Improve Stent Design/Platform 89
5.1.1 Stent Coating Technology 90
5.1.2 Bioabsorbable Stent Technology 92
5.1.3 Antiproliferative Drug and Elution Kinetics 93
5.2 Hybrid Stent Systems 95
5.3 Effective Therapies for Challenging Coronary Indications 96
5.3.1 Chronic Total Occlusions 96
5.3.2 Small-Vessel Disease 96
5.3.3 Bifurcation Lesions 97
5.3.4 Diffuse Atherosclerotic Disease 98
5.3.5 Saphenous Vein Graft Intervention 98
5.3.6 Acute Myocardial Infarction 98
5.4 Target Challenging Patient Populations 99
5.5 Emerging Markets 100
6 Market Drivers, Barriers, and Substitutes 101
6.1 Market Drivers 101
6.1.1 Rising Prevalence of Disease 102
6.1.2 Viable Treatment for Challenging Coronary Indications 103
6.1.3 Innovations in Stent Technology 104
6.1.4 Development of Bioabsorbable Stents 106
6.1.5 Reduce the Need for Prolonged Dual Antiplatelet Therapy 108
6.1.6 Potential Cost Savings 109
6.1.7 Use of Imaging Modalities for Accurate Stent Placement 110
6.1.8 Adoption of Stents in the Emerging Markets 110
6.1.9 Launch of Bioabsorbable Stents in US and Japan 111
6.2 Market Barriers 111
6.2.1 Concerns Regarding Overstenting 111
6.2.2 Post-ProceduraI Complications of Drug-Eluting Stenting 112
6.2.3 Risk of Perioperative Adverse Cardiac Events Post-Stenting 112
6.2.4 Slow Adoption of Bioabsorbable Stents 113
6.2.5 Lack of Reimbursement 118
6.2.6 Healthcare Cost-Cutting and Reimbursement 119
6.2.7 Availability of Venture Capital 120
6.2.8 Medical Device Excise Tax 121
6.3 Market Substitutes 121
6.3.1 Drug-Eluting Balloons 121
6.3.2 Liquid Drug Delivery Catheter 122
7 Competitive Assessment 124
7.1 Overview 124
7.2 Trends in Coronary Stent Technology Development 125
7.2.1 Development of Bare Metal Stents 125
7.2.2 Development of Drug-Eluting Stents 127
7.2.3 Development of Bioabsorbable Stents 130
7.2.4 Development of Covered Stents 131
7.2.5 Coronary Stent Technology SWOT Analysis 132
7.3 Regional Company Market Share 133
7.3.1 EU Market Share 133
8 Pipeline Products 136
8.1 Overview 136
8.2 Pipeline by Stage of Development 136
8.3 Pipeline Product Profiles 139
8.3.1 Bioabsorbable Stents 139
8.3.2 Other Types of Vascular Stents 150
9 Clinical Trial Analysis 156
9.1 Overview 156
9.2 Clinical Trials to Watch 156
9.2.1 Evaluating the Latest and New Generation of Drug-Eluting Stents 156
9.2.2 Bioabsorbable Stent Clinical Trials 158
9.2.3 Evaluating Stenting in Challenging Coronary Indications/Patient Populations 161
9.2.4 Targeting Patient Populations in the APAC Region 163
10 Current and Future Players 165
10.1 Overview 165
10.2 Trends in Corporate Strategy 165
10.3 Company Profiles 168
10.3.1 Abbott Vascular 168
10.3.2 Boston Scientific Corporation 174
10.3.3 Medtronic 181
10.3.4 Alvimedica 187
10.3.5 Amaranth Medical 191
10.3.6 amg International 194
10.3.7 Arterial Remodeling Technologies 198
10.3.8 B. Braun 201
10.3.9 Balton 204
10.3.10 Biosensors International 209
10.3.11 Biotronik 213
10.3.12 Blue Medical 218
10.3.13 Cardionovum 222
10.3.14 C.R. Bard 226
10.3.15 Elixir Medical Corporation 230
10.3.16 eucatech AG 235
10.3.17 Hexacath 239
10.3.18 IRAMED 242
10.3.19 JW Medical Systems 245
10.3.20 Kyoto Medical Planning 248
10.3.21 Lepu Medical Technology 251
10.3.22 MicroPort Scientific Corporation 255
10.3.23 Minvasys 259
10.3.24 MIV Therapeutics 263
10.3.25 Opto Circuits 267
10.3.26 OrbusNeich Medical 271
10.3.27 Relisys Medical Devices 275
10.3.28 REVA Medical 279
10.3.29 Sahajanand Medical Technologies 282
10.3.30 STENTYS 286
10.3.31 Terumo Corporation 290
10.3.32 Translumina 293
10.3.33 Vascular Concepts 297
10.3.34 Other Companies 301
11 Market Outlook 313
11.1 By Market Segment 313
11.1.1 Overview 313
11.1.2 Drug-Eluting Stent Market 314
11.1.3 Bare Metal Stent Market 315
11.1.4 Emerging Stent Technologies 317
11.2 By Indication 319
11.3 By Geography 320
11.3.1 5EU 320
12 Appendix 333
12.1 Bibliography 333
12.2 Abbreviations 357
12.3 Report Methodology 364
12.3.1 Overview 364
12.3.2 Coverage 364
12.3.3 Secondary Research 364
12.4 Physicians and Specialists Included in This Study 366
12.4.1 Praveen Chandra, MD, DM, FESC, FSCAI, FAPSCI 366
12.4.2 Bernado Cortese, MD, FESC 366
12.4.3 Ricardo A. Costa, MD 366
12.4.4 Thomas Cuisset, MD, PhD, FESC 366
12.4.5 Nobuyuki Komiyama, MD, PhD, FACC, FJCC 366
12.4.6 Roger J. Laham, MD 366
12.4.7 Mark W. Mewissen, MD 366
12.4.8 Gary S. Mintz, MD 366
12.4.9 Tudor C. Poerner, MD 367
12.4.10 David Ramsdale, MD, PhD 367
12.4.11 Gregory A. Sgueglia, MD, PhD 367
12.4.12 Madhukar Shahi, MD 367
12.4.13 Takehiro Yamashita, MD, PhD, FACC 367
12.5 Primary Research 368
12.5.1 Primary Research - Key Opinion Leader Interviews 368
12.5.2 Primary Research Interviews- Physician and Industry Participants 368
12.5.3 Physican Survey 369
12.5.4 Expert Panel Validation 370
12.6 Forecasting Methodology 371
12.7 About the Authors 373
12.7.1 Analysts 373
12.7.2 Global Head of Healthcare 374
12.8 About MediPoint 375
12.9 About GlobalData 375
12.10 Disclaimer 375

1.1 List of Tables

Table 1: ACCF/AHA Treatment Guidelines to Improve the Symptoms of CAD* 30
Table 2: Types of CABG 33
Table 3: Complications of CABG 34
Table 4: Drugs Incorporated Into DES 37
Table 5: Types of Lesions Treated Using Atherectomy 41
Table 6: GPOs in the US and EU 54
Table 7: Direct and Indirect Healthcare Costs of CAD 73
Table 8: Healthcare Expenditures ($bn) for CAD in the 5EU, 2006 74
Table 9: US Mean Hospital Costs* ($US) for Cardiac Revascularization Procedures, 2011-2020 75
Table 10: Coronary Stent Technology SWOT Analysis, 2014 132
Table 11: Global Coronary Stent Pipeline Products, 2014 138
Table 12: ART18Z SWOT Analysis, 2014 140
Table 13: DREAMS SWOT Analysis, 2014 141
Table 14: Fantom SWOT Analysis, 2014 142
Table 15: Fortitude SWOT Analysis, 2014 143
Table 16: Ideal BioStent SWOT Analysis, 2014 144
Table 17: Igaki-Tamai Stent SWOT Analysis, 2014 146
Table 18: ON-AVS SWOT Analysis, 2014 147
Table 19: Other Companies Developing BAS, 2014 150
Table 20: FOCUS np Eluting Stent SWOT Analysis, 2014 151
Table 21: STENTYS Sirolimus-Eluting Stent SWOT Analysis, 2014 152
Table 22: Svelte Drug-Eluting Stent SWOT Analysis, 2014 154
Table 23: Clinical Trials Evaluating the Latest and New Generation of DES, 2014 157
Table 24: Clinical Trials Evaluating Stenting in Challenging CAD Indications/Patient Populations, 2014 162
Table 25: Clinical Trials Evaluating Coronary Stenting in APAC Patient Populations, 2014 164
Table 26: Abbott Vascular Company Profile 168
Table 27: Abbott Vascular Coronary Stent Marketed Products 170
Table 28: Abbott Vascular Coronary Stent Product Portfolio SWOT Analysis, 2014 173
Table 29: Abbott Vascular SWOT Analysis, 2014 174
Table 30: Boston Scientific Corporation Company Profile 175
Table 31: Boston Scientific Coronary Stent Marketed Products 177
Table 32: Boston Scientific Coronary Stent Product Portfolio SWOT Analysis, 2014 180
Table 33: Boston Scientific Corporation SWOT Analysis, 2014 181
Table 34: Medtronic Company Profile 182
Table 35: Medtronic Coronary Stent Marketed Products 184
Table 36: Medtronic Coronary Stent Product Portfolio SWOT Analysis, 2014 186
Table 37: Medtronic SWOT Analysis, 2014 187
Table 38: Alvimedica Company Profile 188
Table 39: Alvimedica Coronary Stent Marketed Products 189
Table 40: Alvimedica Coronary Stent Product Portfolio SWOT Analysis, 2014 190
Table 41: Alvimedica SWOT Analysis, 2014 191
Table 42: Amaranth Medical Company Profile 192
Table 43: Amaranth Medical Coronary Stent Pipeline Product 192
Table 44: Amaranth Medical Coronary Stent Product Portfolio SWOT Analysis, 2014 193
Table 45: Amaranth Medical SWOT Analysis, 2014 193
Table 46: amg International Company Profile 194
Table 47: amg International Coronary Stent Marketed Products 196
Table 48: amg International Coronary Stent Product Portfolio SWOT Analysis, 2014 197
Table 49: amg International SWOT Analysis, 2014 198
Table 50: Arterial Remodeling Technologies Company Profile 199
Table 51: Arterial Remodeling Technologies Coronary Stent Pipeline Product 199
Table 52: Arterial Remodeling Technologies Coronary Stent Product Portfolio SWOT Analysis, 2014 200
Table 53: Arterial Remodeling Technologies SWOT Analysis, 2014 200
Table 54: B. Braun Company Profile 201
Table 55: B. Braun Coronary Stent Marketed Products 202
Table 56: B. Braun Coronary Stent Product Portfolio SWOT Analysis, 2014 203
Table 57: B. Braun SWOT Analysis, 2014 204
Table 58: Balton Company Profile 205
Table 59: Balton Coronary Stent Marketed Products 206
Table 60: BALTON Coronary Stent Product Portfolio SWOT Analysis, 2014 208
Table 61: Balton SWOT Analysis, 2014 208
Table 62: Biosensors International Company Profile 209
Table 63: Biosensors International Coronary Stent Marketed Products 211
Table 64: Biosensors International Coronary Stent Product Portfolio SWOT Analysis, 2014 212
Table 65: Biosensors International SWOT Analysis, 2014 213
Table 66: Biotronik Company Profile 214
Table 67: Biotronik Coronary Stent Marketed and Pipeline Products 215
Table 68: Biotronik Coronary Stent Product Portfolio SWOT Analysis, 2014 217
Table 69: Biotronik SWOT Analysis, 2014 218
Table 70: Blue Medical Company Profile 219
Table 71: Blue Medical Coronary Stent Marketed Products 220
Table 72: Blue Medical Coronary Stent Product Portfolio SWOT Analysis, 2014 221
Table 73: Blue Medical SWOT Analysis, 2014 222
Table 74: Cardionovum Company Profile 223
Table 75: Cardionovum Coronary Stent Marketed and Pipeline Products 224
Table 76: Cardionovum Coronary Stent Product Portfolio SWOT Analysis, 2014 225
Table 77: Cardionovum SWOT Analysis, 2014 226
Table 78: C.R. Bard Company Profile 227
Table 79: ClearStream Technologies Coronary Stent Marketed Products 228
Table 80: C.R. Bard Coronary Stent Product Portfolio SWOT Analysis, 2014 229
Table 81: C.R. Bard SWOT Analysis, 2014 230
Table 82: Elixir Medical Corporation Company Profile 231
Table 83: Elixir Medical Corporation Coronary Stent Marketed Products 232
Table 84: Elixir Medical Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014 234
Table 85: Elixir Medical Corporation SWOT Analysis, 2014 235
Table 86: eucatech Profile 236
Table 87: eucatech Coronary Stent Marketed Products 237
Table 88: eucatech Coronary Stent Product Portfolio SWOT Analysis, 2014 238
Table 89: eucatech SWOT Analysis, 2014 239
Table 90: Hexacath Company Profile 240
Table 91: Hexacath Coronary Stent Marketed Products 241
Table 92: Hexacath Coronary Stent Product Portfolio SWOT Analysis, 2014 241
Table 93: Hexacath SWOT Analysis, 2014 242
Table 94: IRAMED Company Profile 242
Table 95: IRAMED Coronary Stent Marketed Products 243
Table 96: IRAMED Coronary Stent Product Portfolio SWOT Analysis, 2014 244
Table 97: IRAMED SWOT Analysis, 2014 245
Table 98: JW Medical Systems Company Profile 246
Table 99: JW Medical Systems Coronary Stent Marketed Product 246
Table 100: JW Medical Systems' Coronary Stent Product Portfolio SWOT Analysis, 2014 247
Table 101: JW Medical Systems SWOT Analysis, 2014 248
Table 102: Kyoto Medical Planning Company Profile 249
Table 103: Kyoto Medical Planning Coronary Stent Pipeline Product 250
Table 104: Kyoto Medical Planning Coronary Stent Product Portfolio SWOT Analysis, 2014 250
Table 105: Kyoto Medical Planning SWOT Analysis, 2014 251
Table 106: Lepu Medical Technology Company Profile 252
Table 107: Lepu Medical Technology Coronary Stent Marketed and Pipeline Products 253
Table 108: Lepu Medical Technology Coronary Stent Product Portfolio SWOT Analysis, 2014 254
Table 109: Lepu Medical Technology SWOT Analysis, 2014 255
Table 110: MicroPort Scientific Corporation Company Profile 256
Table 111: MicroPort Scientific Corporation Coronary Stent Marketed Products 257
Table 112: MicroPort Scientific Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014 258
Table 113: MicroPort Scientific Corporation SWOT Analysis, 2014 259
Table 114: Minvasys Company Profile 260
Table 115: Minvasys Coronary Stent Marketed and Pipeline Products 261
Table 116: Minvasys Coronary Stent Product Portfolio SWOT Analysis, 2014 262
Table 117: Minvasys SWOT Analysis, 2014 263
Table 118: MIV Therapeutics Company Profile 264
Table 119: MIV Therapeutics Coronary Stent Marketed Products 265
Table 120: MIV Therapeutics Coronary Stent Product Portfolio SWOT Analysis, 2014 266
Table 121: MIV Therapeutics SWOT Analysis, 2014 267
Table 122: Opto Circuits Company Profile 268
Table 123: Opto Circuits Coronary Stent Marketed Products 269
Table 124: Opto Circuits Coronary Stent Product Portfolio SWOT Analysis, 2014 270
Table 125: Opto Circuits SWOT Analysis, 2014 271
Table 126: OrbusNeich Medical Company Profile 272
Table 127: OrbusNeich Medical Coronary Stent Marketed and Pipeline Products 273
Table 128: OrbusNeich Medical Coronary Stent Product Portfolio SWOT Analysis, 2014 274
Table 129: OrbusNeich Medical SWOT Analysis, 2014 275
Table 130: Relisys Medical Devices Company Profile 276
Table 131: Relisys Medical Devices Coronary Stent Marketed Products 277
Table 132: Relisys Medical Devices Coronary Stent Product Portfolio SWOT Analysis, 2014 278
Table 133: Relisys Medical Devices SWOT Analysis, 2014 279
Table 134: REVA Medical Company Profile 280
Table 135: REVA Medical Coronary Stent Pipeline Product 280
Table 136: REVA Medical Coronary Stent Product Portfolio SWOT Analysis, 2014 281
Table 137: REVA Medical SWOT Analysis, 2014 282
Table 138: Sahajanand Medical Technologies Company Profile 283
Table 139: Sahajanand Medical Technologies Coronary Stent Marketed and Pipeline Products 284
Table 140: Sahajanand Medical Technologies Coronary Stent Product Portfolio SWOT Analysis, 2014 285
Table 141: Sahajanand Medical Technologies SWOT Analysis, 2014 286
Table 142: STENTYS Company Profile 287
Table 143: STENTYS Coronary Stent Marketed and Pipeline Products 288
Table 144: STENTYS Coronary Stent Product Portfolio SWOT Analysis, 2014 289
Table 145: STENTYS SWOT Analysis, 2014 289
Table 146: Terumo Corporation Company Profile 290
Table 147: Terumo Corporation Coronary Stent Marketed and Pipeline Products 291
Table 148: Terumo Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014 292
Table 149: Terumo Corporation SWOT Analysis, 2014 293
Table 150: Translumina Company Profile 294
Table 151: Translumina Coronary Stent Marketed Products 295
Table 152: Translumina Coronary Stent Product Portfolio SWOT Analysis, 2014 296
Table 153: Translumina SWOT Analysis, 2014 296
Table 154: Vascular Concepts Company Profile 297
Table 155: Vascular Concepts Coronary Stent Marketed Products 298
Table 156: Vascular Concepts Coronary Stent Product Portfolio SWOT Analysis, 2014 299
Table 157: Vascular Concepts SWOT Analysis, 2014 300
Table 158: Other Companies in the Coronary Stent Market, North America, 2014 301
Table 159: Other Companies in the Coronary Stent Market, EU, 2014 306
Table 160: Other Companies in the Coronary Stent Market, APAC, 2014 309
Table 161: Other Companies in the Coronary Stent Market, South Africa and South America, 2014 312
Table 162: Global Coronary Stent Sales ($m) Forecast, by Segment, 2011-2020 313
Table 163: Global DES Sales ($m) Forecast, 2011-2020 314
Table 164: Global BMS Sales ($m) Forecast, 2011-2020 316
Table 165: EU Coronary Stent Sales ($m) Forecast, by Segment, 2011-2020 320
Table 166: Coronary Stents Market Sales ($m) Forecast for France, 2011-2020 322
Table 167: Coronary Stents Market Sales ($m) Forecast for Germany, 2011-2020 324
Table 168: Coronary Stents Market Sales ($m) Forecast for Italy, 2011-2020 327
Table 169: Coronary Stents Market Sales ($m) Forecast for Spain, 2011-2020 329
Table 170: Coronary Stents Market Sales ($m) Forecast for the UK, 2011-2020 331
Table 171: Primary Research Interviews Completed 369
Table 172: Physicians Surveyed, By Country 370

1.2 List of Figures

Figure 1: Pathophysiology of CAD 28
Figure 2: CAD Treatment Modalities 31
Figure 3: Percentage of Patients with CAD Who Receive Each Therapy Option Only, Global, 2012 and 2019 (N=58) 32
Figure 4: Percentage of Patients with CAD Who Receive Each Type of PCI Only, Global, 2012 and 2019 (N=58) 35
Figure 5: Types of Stents Used to Treat CAD 36
Figure 6: Example of a BMS 37
Figure 7: Example of a DEB 40
Figure 8: Types of Atherectomy 42
Figure 9: 5EU Coronary Stenting Procedure Volume, 2011-2020 46
Figure 10: US Mean Hospital Costs* ($US) for Cardiac Revascularization Procedures, 2011-2020 75
Figure 11: Percentage of CAD Patients with ISR, Global, 2012 and 2018 (N=58) 83
Figure 12: Percentage of CAD Patients Who Receive Stent-In-Stent Procedures, Global, 2012 and 2018 (N=58) 85
Figure 13: Interventional Cardiologists' Ranking of the Importance of Each Therapy Attribute in Adopting Stents for the Treatment of CAD, Global, 2013 (N=101) 90
Figure 14: Global Coronary Stents Market Value Share (%), 2013 and 2020 125
Figure 15: EU Market Share for BMS (%), 2013 134
Figure 16: EU Market Share for DES (%), 2013 135
Figure 17: Global Coronary Stent Pipeline Products by Stage of Development, 2014 137
Figure 18: Global Coronary Stents Market Revenue ($m), 2011-2020 314
Figure 19: Global DES Market Revenue ($m), 2011-2020 315
Figure 20: Global BMS Market Revenue ($m), 2011-2020 316
Figure 21: Percentage of Patients (%) Treated with Each Type of Coronary Stent Only, Global, 2013 and 2020 (N=101) 318
Figure 22: Percentage of Patients (%) Treated with Coronary Stents for Each Indication, Global, 2013 and 2020 (N=101) 319
Figure 23: EU Sales ($m) Forecast for Coronary Stents, 2011-2020 321
Figure 24: French Sales ($m) Forecast for Coronary Stents, 2011-2020 323
Figure 25: German Sales ($m) Forecast for Coronary Stents, 2011-2020 325
Figure 26: Italian Sales ($m) Forecast for Coronary Stents, 2011-2020 327
Figure 27: Spanish Sales ($m) Forecast for Coronary Stents, 2011-2020 329
Figure 28: UK Sales ($m) Forecast for Coronary Stents, 2011-2020 331

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
European Market Report for Dialysis Catheters 2017 - MedCore

European Market Report for Dialysis Catheters 2017 - MedCore

  • $ 6495
  • Industry report
  • November 2016
  • by iData Research, Inc.

Description The European market for dialysis catheters comprises the acute hemodialysis, chronic hemodialysis and peritoneal dialysis catheter segments. The chronic hemodialysis catheter market is segmented ...

MediPoint: Percutaneous Coronary Interventions - Global Analysis and Market Forecasts

MediPoint: Percutaneous Coronary Interventions - Global Analysis and Market Forecasts

  • $ 5995
  • Industry report
  • October 2016
  • by Global Data

MediPoint: Percutaneous Coronary Interventions - Global Analysis and Market Forecasts Summary Coronary stents, which include bare metal stents, drug-eluting stents (DESes), covered stents, and bioabsorbable ...

Vascular Access Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024

Vascular Access Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024

  • $ 5795
  • Industry report
  • September 2016
  • by Transparency Market Research

Vascular Access Devices Market: Scope and Methodology Vascular access devices are medical devices used to obtain access to the bloodstream, and are hollow and flexible tubes made of latex, silicone, and ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.